Traws Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-166.52	-18.95	-18.96	-16.16	-25.16	Upgrade
Depreciation & Amortization	0.01	0.02	0.01	0.01	0.01	Upgrade
Asset Writedown & Restructuring Costs	117.46	-	-	-	-	Upgrade
Stock-Based Compensation	1.39	1.3	1.17	0.58	0.37	Upgrade
Other Operating Activities	24.44	-	-	-0.32	0.21	Upgrade
Change in Accounts Receivable	-1.75	0.01	-0	0.01	0.06	Upgrade
Change in Accounts Payable	0.65	1.76	1.1	-2.08	0.56	Upgrade
Change in Unearned Revenue	-0.23	-0.23	-0.23	-0.23	-0.23	Upgrade
Change in Other Net Operating Assets	-5.25	-1.85	0.61	-1.3	1.1	Upgrade
Operating Cash Flow	-29.79	-17.93	-16.29	-19.49	-23.08	Upgrade
Capital Expenditures	-	-0.01	-	-	-0.02	Upgrade
Cash Acquisitions	-3.65	-	-	-	-	Upgrade
Investing Cash Flow	-3.65	-0.01	-	-	-0.02	Upgrade
Issuance of Common Stock	33.98	-	-	55.56	19.36	Upgrade
Financing Cash Flow	33.98	-	-	55.56	19.36	Upgrade
Foreign Exchange Rate Adjustments	-0.02	0.01	-0.02	-0.03	0.03	Upgrade
Net Cash Flow	0.52	-17.94	-16.31	36.05	-3.7	Upgrade
Free Cash Flow	-29.79	-17.95	-16.29	-19.49	-23.09	Upgrade
Free Cash Flow Margin	-13182.30%	-7940.71%	-7209.74%	-8622.57%	-9995.67%	Upgrade
Free Cash Flow Per Share	-19.19	-21.38	-19.48	-28.94	-49.75	Upgrade
Levered Free Cash Flow	-13.63	-11.46	-9.38	-13.23	-13.54	Upgrade
Unlevered Free Cash Flow	-13.63	-11.46	-9.38	-13.23	-13.54	Upgrade
Change in Net Working Capital	-0.54	0.08	-1.7	3.51	-1.72	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q